Please join PPMD for a community webinar with REGENXBIO, who will share topline results from the pivotal portion of the AFFINITY DUCHENNE trial evaluating RGX-202, the company’s investigational gene therapy for Duchenne muscular dystrophy. REGENXBIO will review key findings from the pivotal study, including data on microdystrophin expression and interim safety and functional outcomes.
Submit questions in advance here.
